Duchenne muscular dystrophy

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Buoyed by new data, Santhera preps filing for DMD drug vamor...

A year ago, Swiss biotech Santhera was slashing staff to cut costs after it abandoned lead Duchenne muscular dystrophy (DMD) therapy idebenone.

News

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

Capricor Therapeutics' bid to find a partner for its Duchenne muscular dystrophy (DMD) cell therapy CAP-1002 could get a boost after final phase 2 data showed a strong effect on disease pro

News

DNA helix in a futuristic concept of the evolution of science and medicine.

First UK patient joins Pfizer's phase 3 DMD gene therapy tri...

The first UK patient has enrolled on Pfizer’s phase 3 trial for its Duchenne muscular dystrophy (DMD) gene therapy.

News

Scotland opens door to Translarna for Duchenne muscular dyst...

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland gave a green light to use of PTC Therapeutics' Translarna for the first time.

News

Catabasis craters after giving up on muscular dystrophy lead

Catabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after a phase 3 trial echoed the results of a failed mid-stage study.

News

NS Pharma takes on Sarepta as FDA approves DMD drug

The FDA has approved a new therapy for the rare muscle wasting disease Duchenne muscular dystrophy (DMD) as Japan’s NS Pharma takes on Sarepta and its controversially approved rival.

Buoyed by new data, Santhera preps filing for DMD drug vamor...

Capricor preps phase 3 for Duchenne cell therapy as it seeks...

First UK patient joins Pfizer's phase 3 DMD gene therapy tri...

Scotland opens door to Translarna for Duchenne muscular dyst...

Catabasis craters after giving up on muscular dystrophy lead

NS Pharma takes on Sarepta as FDA approves DMD drug

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Duchenne muscular dystrophy

Editor's Picks